Combination of KDM6B Inhibitor and Immune Checkpoint Blockade Therapy for Use in a Method of Treating Glioblastoma
Summary
The European Patent Office published patent application EP4149512A1 on April 8, 2026. The patent covers a combination therapy using KDM6B inhibitors with immune checkpoint blockade for treating glioblastoma. Applicants are the Board of Regents, The University of Texas System, with inventors including Goswami, Sharma, and Allison.
What changed
The European Patent Office published patent EP4149512A1, covering a combination therapy combining KDM6B inhibitors with immune checkpoint blockade for treating glioblastoma. The patent names the Board of Regents, The University of Texas System as applicants, with inventors Goswami, Sharma, and Allison. The designated states cover major European jurisdictions.
This patent publication is relevant to pharmaceutical and biotechnology companies developing cancer immunotherapies. It may affect freedom-to-operate analyses and licensing considerations for parties working in the glioblastoma treatment space. The document is informational and imposes no compliance obligations on third parties.
Archived snapshot
Apr 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION OF KDM6B INHIBITOR AND IMMUNE CHECKPOINT BLOCKADE THERAPY FOR USE IN A METHOD OF TREATING GLIOBLASTOMA
Publication EP4149512A1 Kind: A1 Apr 08, 2026
Applicants
Board of Regents, The University of Texas System
Inventors
GOSWAMI, Sangeeta, SHARMA, Padmanee, ALLISON, James
IPC Classifications
A61K 31/713 20060101AFI20240502BHEP A61K 31/55 20060101ALI20240502BHEP A61K 38/00 20060101ALI20240502BHEP A61K 45/06 20060101ALI20240502BHEP C07K 16/40 20060101ALI20240502BHEP A61P 25/00 20060101ALI20240502BHEP A61P 35/00 20060101ALI20240502BHEP A61K 39/395 20060101ALI20240502BHEP C07K 16/28 20060101ALI20240502BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.